{"id":"W4323307162","doi":"10.1159/000529996","title":"Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Bevacizumab; Medicine; Atezolizumab; Sorafenib; Internal medicine; Hepatocellular carcinoma; Liver function; Gastroenterology; Population; Post-hoc analysis; Oncology; Tolerability; Clinical endpoint; Surgery; Randomized controlled trial; Adverse effect; Cancer; Chemotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002149375,0.0003577183,0.001151513,0.000907575,0.00009801365,0.00001571458,0.0002946681,0.0001100433,0.0002932459],"category_scores_gemma":[0.00003696513,0.0002375717,0.0004547224,0.004874063,0.0001632205,0.0001104836,0.000156504,0.000206168,0.000006681504],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004130697,"about_ca_system_score_gemma":0.0004216397,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01803069,"about_ca_topic_score_gemma":0.003903497,"domain_scores_codex":[0.9971956,0.000208717,0.0006358304,0.0005623641,0.0009235664,0.0004739446],"domain_scores_gemma":[0.9982098,0.0001451163,0.0003329608,0.0008242902,0.0003477253,0.0001401601],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01316637,0.001944463,0.9751662,0.0001228035,0.004339172,0.0002045936,0.00321587,0.0001882633,0.0009952849,0.00000492647,0.0000455123,0.0006065221],"study_design_scores_gemma":[0.05404129,0.004155851,0.8965807,0.0001035102,0.01154775,8.058176e-7,0.001324165,0.01710134,0.01482604,0.00000171205,0.00003371357,0.0002831545],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961253,0.001356503,0.000002603258,0.00007284853,0.000113634,0.001950885,0.0002655359,0.00003550873,0.00007720209],"genre_scores_gemma":[0.9990663,0.00009141218,0.00001759287,0.00001973567,0.00002834502,0.0002022476,0.000276749,0.00004292318,0.0002547141],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07858555,"threshold_uncertainty_score":0.9885083,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09168397289620757,"score_gpt":0.3275482401496349,"score_spread":0.2358642672534274,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}